A Phase 2/3 Study of SYR-322 as an Add-on to a Sulfonylurea

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080220603

Enrollment

240

Registered

2008-09-05

Start date

2008-09-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus.

Interventions

investigational material(s) Generic name etc : SYR-322 INN of investigational material : Therapeutic category code : 396 Antidiabetic agents Dosage and Administration for Investigational material : O

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Key Criteria for inclusion: The subject has been taking a sulfonylurea for at least 4 weeks prior to the initiation of the observation period. The subject has been taking sulfonylurea at a stable dose regimen for at least 12 weeks prior to the initiation of the treatment period(Week 0). The subject has an HbA1C of 7.0% or more and below 10.0% at 8 weeks after the initiation of the observation period(Week -4).

Exclusion criteria

Exclusion criteria: Key Criteria for exclusion: The subject has taken other diabetic medications than sulfonylurea within 12 weeks before the initiation of the treatment period (Week 0).

Design outcomes

Primary

Measure	Time frame
HbA1c change at the completion of treatment from baseline	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026